TILs Show Growing Potential as Novel Immunotherapy
October 5th 2018Although checkpoint-blocking antibodies dominate the anticancer immunotherapy field today, researchers are increasingly exploring the potential to leverage growing knowledge about tumor-infiltrating lymphocytes to develop new drugs.
Read More